Comparing Pathfinder Cell Therapy (OTCMKTS:PFND) and Precigen (NASDAQ:PGEN)

Precigen (NASDAQ:PGEN) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Precigen and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precigen	-2,868.66%	-842.83%	-78.98%
Pathfinder Cell Therapy	N/A	N/A	N/A

Valuation and Earnings

This table compares Precigen and Pathfinder Cell Therapy”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$3.92 million	342.82	-$126.24 million	($0.42)	-10.74
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Pathfinder Cell Therapy has lower revenue, but higher earnings than Precigen.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Precigen and Pathfinder Cell Therapy, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	0	1	4	0	2.80
Pathfinder Cell Therapy	0	0	0	0	0.00

Precigen currently has a consensus target price of $8.25, indicating a potential upside of 82.93%. Given Precigen’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Precigen is more favorable than Pathfinder Cell Therapy.

Institutional and Insider Ownership

33.5% of Precigen shares are owned by institutional investors. 47.1% of Precigen shares are owned by insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Precigen beats Pathfinder Cell Therapy on 6 of the 9 factors compared between the two stocks.

About Precigen

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.